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Background: Clear cell renal cell carcinoma (ccRCC) cell lines with distinct metastatic potential are essential to
study the mechanism of ccRCC metastasis. However, none of them originated from Chinese.
Methods: Primary cell cultures were performed using a primary tumor of a 49-year-old male ccRCC patient and a
metastatic tumor of a 62-year-old male patient who had received nephrectomy to excise primary ccRCC 10 years
ago. Cell growth, microstructure, cytogenetics, cytometry, expression of metastasis-associated molecules,
tumorigenesis and metastasis were subsequently characterized.
Results: Two successive cell lines named NRCC from the primary ccRCC and MRCC from the metastatic ccRCC were
established, respectively. Compared to NRCC, MRCC exhibited stronger anchorage-independent growth and
invasion potentials and contained more glycogen granules in the cytoplasm. Gains of chromosomes and some
translocations were the major chromosomal aberrations in both cell strains. CD24 expression was more frequent in
MRCC than in NRCC and the same was true for CD56. The transcriptional levels of TNFα, IL-6, VEGF, HIF2α, MMP2,
and RhoC were significantly higher in MRCC than in NRCC. Cytosolic IκBα protein was more degraded in MRCC
than in NRCC following TNFα treatment. Both cell lines had strong tumorigenicity in athymic nude mice. However,
MRCC had strong potential in generating metastasis to lung and hemorrhagic ascites than NRCC following
orthotopic transplantations.
Conclusions: Cancer cells isolated from metastatic ccRCC have more malignant and metastatic potential than
those from the primary tumor from the patients who shared the similar race background. Establishment of MRCC
and NRCC may provide suitable models with which to investigate molecular mechanisms of ccRCC metastasis.
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The incidence of renal cell carcinoma (RCC) varies
substantially worldwide. The rates are generally high in
Europe and North America while low in Asia and South
America [1]. RCC is a pathologically heterogeneous dis-
ease and can be subdivided into clear, papillary, granular,
spindle, and mixed cell subtypes based on cytoplasmic fea-
tures. Clear cell RCC (ccRCC) is the most common type
(70%-80%) and accounts for most cases of metastatic* Correspondence: gcao@smmu.edu.cn
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reproduction in any medium, provided the ordisease. Metastatic RCC is a highly fatal disease, which ac-
counts for about a third of the patients at initial presenta-
tion. Approximately 10% to 28% of RCC develop a local
recurrence or distant metastasis after curative nephrec-
tomy [2]. Metastatic RCC is resistant to chemotherapy
and radiotherapy but responds to tyrosine kinase inhibi-
tors and interleukin-2-based immunotherapy [3,4].
Asian and non-Asian populations exhibit big differences
in the incidence of RCC, environmental and genetic risk
factors, and even adverse effects of the treatment with
sorafenib and sunitinib [1,5,6]. Genetic background should
be important in exploring the mechanism of renal car-
cinogenesis and developing therapeutic option. RCC cell. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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derstanding RCC biology and the mechanism of metasta-
sis and also beneficial for identification of therapeutic
approaches to improve the prognosis. Several RCC cell
lines have been isolated and characterized [7,8]. However,
ccRCC cell lines with characterized metastatic potential
are very rare and none of them were from Chinese.
In this study, we characterized the two ccRCC cell
lines with different metastatic potential. One was derived
from primary ccRCC and the other was from a meta-
static ccRCC. The comparable cell lines can be used for
exploration of metastasis mechanism, selection of thera-
peutic compounds, and development of ccRCC vaccines.
To our knowledge, this is the first report of the estab-
lishment of ccRCC cell lines from Chinese patients.
Results
Establishment of ccRCC cell lines
We succeeded in maintaining the cultured cells from clin-
ical specimens of the two patients and culturing them for
more than 100 generations in DMEM with 10% FCS. The
cells from both patients were proven to have strong
tumorigenicity in nude mice. Primary cultures were also
made using the subcutaneous and orthotropic tumors de-
rived from the two cell lines. The successive ccRCC cell
lines derived from the metastatic site of the patient
(No.375771) and from the primary ccRCC tissue of the
patient (No.378570) were termed as MRCC and NRCC,
respectively. MRCC and NRCC cells were reserved in
Chinese Center for Type Culture Collection (CCTCC)
with store numbers CCTCC-C200909 and CCTCC-
C200910, respectively. The following assays were carried
out using the two cell lines of 50–60 generations.
Morphology of MRCC and NRCC
Figure 1 shows the morphology of the cell lines and par-
ental tissues. The cell lines had clear cytoplasm, roundFigure 1 Morphology of MRCC and NRCC cells. (a-c) MRCC; (d-f) NRCC;
cell culture, H&E staining.to oval nuclei with one or two nucleoli, and high
nuclear-to-cytoplasmic ratio. NRCC cells were typically
epithelial-like and spindle-shaped and proliferated in a
pavement-like cell arrangement with distinct border. As
compared to NRCC, MRCC cells were relatively larger
in size with irregular shapes and a lack of distinct border.
MRCC proliferated in a pavement-like cell arrangement
with a lack of contact inhibition. The entire cells of MRCC
and NRCC were shown as Figure 2a and 2e, respectively.
The two cell lines were of epithelial cell origin as micro-
villi detected on their cell surfaces (Figure 2b and 2g). Ul-
trastructurally, the cell lines displayed characteristic filmy
cytoplasm containing abundant glycogen granules, lipid
droplets, and poorly developed mitochondria (Figure 2c
and 2f) and nuclei with prominent nucleoli, which was
consistent with the previous EM findings of ccRCC [8,9].
Interestingly, the glycogen granules were more clustered
in MRCC than in NRCC (Figure 2d and 2h).
Growth kinetics and invasion ability
The doubling times of NRCC cells and MRCC cells were
35.5 h and 55.2 h, respectively. However, MRCC cells
showed stronger anchorage-independent growth than
NRCC cells. Colony formation rates of MRCC cells and
NRCC cells in the agarose were 45.3% ± 4.9% and 31.7% ±
4.5% (p < 0.05), respectively. In the invasion assay, it was
found that the invasive capacity of MRCC cells surpassed
that of NRCC cells (average invasion rates: 43.6% ± 5.8%
vs. 30.2% ± 4.6%, p < 0.001). These results indicated that
MRCC cells could be more invasive than NRCC cells.
Cytogenetic characteristics
The number of chromosomes in MRCC cells ranged
from 45 to 68 with a modal number of 66; while that in
NRCC cells ranged from 53 to 86 with a modal number
of 82. Gains of chromosomes, rather than loss of chro-
mosomes, were the major abnormalities in chromosome(a, d) the corresponding tumors, H&E staining; (b, e) cell culture; (c, f)
Figure 2 EM findings. (a-d) MRCC; (e-h) NRCC; (a, e) the entire cell; (b) nucleus and microvilli (red arrow); (c) glycogen granules and
mitochondria; (d, h) glycogen granules accumulated; (f) nucleus and mitochondria; (g) glycogen granules and microvilli (red arrow).





Gain Frequency(%, n/N) †
Gain Frequency
(%, n/N) †
1 - - 1-4 100.0 (30/30)
2 1 63.6 (19/30) 1-2 100.0 (30/30)
4 - - 1-2 90.0 (27/30)
5 1-2 100.0 (30/30) 1-3 96.7 (29/30)
Tan et al. Cancer Cell International 2013, 13:20 Page 3 of 11
http://www.cancerci.com/content/13/1/20number. Table 1 shows the gain of chromosomes in the
two cell lines. Two significant chromosomal transloca-
tions, der(6)t(3qter→ q12::6q11→ pter) and der(11)t
(11pter→ q23::1q23→ qter) were identified in 80.0%
and 96.7% of MRCC cells, respectively. Furthermore, a
marker chromosome (mar1) was observed in 93.3% of
MRCC cells. One deletion, del(4)(pter→ q25:) and a
translocation, der(1)t(1qter→ q11::13q11→ qter) were
found in 93.3% and 36.7% of NRCC cells, respectively.
Figure 3 presents typical karyotype of each cell line for
chromosomal abnormality in both number and structure.6 1 70.0 (21/30) 1-2 96.7 (29/30)
7 1-3 93.3 (28/30) 1-3 93.3 (28/30)
8 - - 1-2 90.0 (27/30)
10 - - 1-3 90.0 (27/30)
11 1 96.7 (29/30) 1-3 93.3 (28/30)
12 1-2 93.3 (28/30) 1-2 93.3 (28/30)
13 - - 1-2 83.3 (25/30)
15 - - 1-3 96.7 (29/30)
16 1 66.7 (20/30) 2-4 93.3 (28/30)
17 1-2 80.0 (24/30) 1-3 96.7 (29/30)
19 1-2 73.3 (22/30) 1-4 96.7 (29/30)
20 1-3 96.7 (29/30) - -
21 - - 1-3 90.0 (27/30)
22 - - 1-2 96.7 (29/30)
† n, the number of metaphases with gain(s) of chromosome(s); N, total
number of metaphases observed.Expression of cell markers
Taking into account a previous report about stem-like
cell markers of ccRCC [10], we examined the expression
of CD105, CD133, CD44, CD24, CD56, CD99, and
CD74 on MRCC and NRCC cells by cytometry. It was
found that both cell lines were positive for CD44 but
negative for CD133, CD105, and CD74. The positive rate
of CD24 was higher in MRCC cells (Figure 4a) than in
NRCC cells (Figure 4b) and the same was true for CD56.
However, the positive rate of CD99 was higher in NRCC
cells than in MRCC cells. We also examined the expres-
sion of epithelial and mesenchymal markers. In contrast
to N-cadherin expression, E-cadherin expression was
less frequent in MRCC cells than in NRCC cells. The ex-
pression of vimentin was a little higher in MRCC cells
than in NRCC cells. These data indicated that NRCC
Figure 3 Representative G-banding karyotypes of MRCC and NRCC. (a) MRCC; (b) NRCC. mar1, a marker chromosome.
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MRCC cells tended to be more mesenchymal-like.
Cell cycle analysis
Cell cycle analysis showed that 18.9% of MRCC cells
were in S phase; while 13.8% of NRCC were in S phase
(Figure 5). Interestingly, a typical sub-G1 peak was fre-
quently detected in NRCC cells, rather than in MRCC
cells, indicating a possible apoptosis undertaken in
NRCC cells.
Expression of metastasis-associated molecules
Since the doubling times of the two cell lines were dif-
ferent, the transcription of interleukin-6 (IL-6), tumor ne-
crosis factor-α (TNFα), vascular endothelial growth factor
(VEGF), matrix metalloproteinase-2 (MMP2), hypoxia-
inducible factor (HIF) 1α, HIF2α, glycogen synthase kin-
ase 3 beta (GSK3ß), RhoC, Ubiquitin specific peptidase 6
(USP6), AHNAK nucleoprotein (AHNAK), Leucine-rich re-
peat kinase 2 (LRRK2), SLIT-ROBO Rho GTPase activatingprotein 3 (SRGAP3) in MRCC cells and NRCC cells were
examined at 24 h, 48 h and 72 h, respectively, after cell
split. The expression patterns of the examined genes are
shown in Figure 6. In general, the expression of the most
genes at 24 h culture wasn’t significant different between
MRCC and NRCC cells, except that the expression of
TNFa, IL-6, and AHNAK was significantly higher in
MRCC cells than in NRCC cells (p < 0.05 for each). To-
gether with cell invasion assay performed at 24 h after
cell split, the three genes were supposed to be involved
in cell mobility and invasion. The expression of LRRK2
and USP6 was not significantly different between MRCC
and NRCC cells. The expression of SRGAP3 was signifi-
cantly higher in NRCC than in MRCC cells at 48 h and
72 h after cell spilt (p < 0.05). The levels of TNFα, IL-6,
VEGF, and MMP2 were higher in MRCC cells than in
NRCC cells at 72 h after cell split (p < 0.05 for each).
The same trend was observed for HIF2α expression at
48 h after cell split (p < 0.05). However, the expression of
HIF1α was higher in NRCC cells than in MRCC cells
Figure 4 Flow cytometry for the analyses of CD56, CD24, CD99, vimentin, E- cadherin, N-cadherin expression in MRCC and NRCC. (a)
MRCC; (b) NRCC.
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nificant level. The expression of GSK3β was lower in
MRCC cells than in NRCC cells at 72 h after cell split
(p < 0.05). Furthermore, the RhoC expression was higher
in MRCC cells than NRCC cells at 48 h after cell split
(p < 0.05). Western blot indicated that cytosolic IκBα
protein was more degraded in MRCC cells than in
NRCC cells within 60 min after the in vitro treatment
with TNFα (Figure 7), indicating nuclear factor-kappa B(NF-κB) signaling pathway is more active in MRCC than
in NRCC cells.
Metastatic potential of MRCC and NRCC in nude mice
Subcutaneous transplantation of MRCC cells or NRCC
cells generated tumors in nude mice within two weeks.
No lung metastasis was detected following the first round
of surgical orthotopic implantation (SOI) with MRCC and
NRCC tumors. However, ccRCC metastasized to lung was
Figure 5 DNA content of the ccRCC cell lines by flow
cytometry. (a) MRCC; (b) NRCC.
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SOI with MRCC tumors, and the incidence of lung metas-
tasis was nearly 100%. Furthermore, the metastasis to
lymph nodes near ventral aorta and hemorrhagic ascites
were frequently evident in the SOI mice transplanted with
MRCC tumors. With the increase of the cycles of the
transplantation with MRCC, the duration of orthotopic
tumor formation to about 10 mm in diameter became
shorter and the incidences of hemorrhagic ascites and
cachexy became higher (Table 2). We isolated and
established the metastatic cell strain from pulmonary
tumor mass, named MRCC-L. MRCC-L looked smaller in
size and grew faster in vitro than their parental MRCC.
Orthotopic transplantation of NRCC also generated
tumor in all mice. However, metastasis was not observed
at the first three rounds of the transplantation with NRCC
cells. These data suggested that MRCC had higher malig-
nant and metastatic potential than NRCC.
Discussion
In this study, we successfully established two ccRCC cell
lines from two Chinese patients with ccRCC. Up to now,
the two cell lines have been maintained in our laboratory
for 6 years and cultured for more than 100 passages.
The two patients were comparable on the aspects of
race, sex, and age at onset of primary ccRCC. Although
the microenvironment plays an important role in evolu-
tionary process of the metastatic cells from their primary
tumors, the selected metastatic cancer cells maintain
their characteristics following long-term in vitro cul-
tures. In vivo study demonstrated that MRCC cells
exhibited more malignant and metastatic potential thanNRCC (Table 2). Therefore, the differences in cellular
and subcellular morphology, cell growth/invasion ability,
cytogenetics, cell markers, and expression pattern of
metastasis-associated molecules between the two cell
lines can designate, at least partially, some important cel-
lular and molecular events related to ccRCC metastasis.
The current study characterized the cell lines of 50–60
generations. It was found that MRCC grew a little slower
but exhibited stronger anchorage-independent growth po-
tential than NRCC in vitro. The invasion study indicated
MRCC had higher invasion potential than NRCC. Analysis
of cell cycle at the same pace of proliferation suggested that
MRCC were more frequent in S phase whereas NRCC
displayed a typical sub-G1 peak. Thus, compared to
NRCC, MRCC exhibited “low proliferation-high invasion-
low apoptosis” cell kinetic profile. This is probably related
to a large number of glycogen particles stored in the cyto-
plasm. The “glassy” cytoplasm appearance of ccRCC
might be due to glycogen and sterol storage caused by ab-
normalities in carbohydrate and lipid metabolism [9,11].
GSK3 is a protein kinase that phosphorylates and inacti-
vates glycogen synthase, the final enzyme of glycogen bio-
synthesis [12]. In this study, we found that GSK3β, an
important member of GSK3 family, was higher expressed
in NRCC than in MRCC (Figure 6). The level of GSK3β
may be reversely related to glycogen storage in RCC cells.
Glycogen-rich carcinomas of clear cell subtype are usually
characterized by a peculiar “low proliferation-low apop-
tosis” cell kinetic profile and associated with cancer ag-
gressiveness [11,13]. Thus, the level of GSK3β might be
reversely related to ccRCC metastasis.
Loss of chromosomal materials on 3p, 8p, 9p, and 14q
has been documented in 96%, 22%, 33%, and 41% of
ccRCC cases, respectively [14]. The von Hippel Lindau
(VHL) tumor suppressor gene on chromosome 3p and
stabilization of HIF1α due to loss of VHL function has
been shown to be central to development of ccRCC [15].
However, the cytogenetic abnormalities on chromo-
somes 3p and the difference in HIF1α levels were not
found in this study. With the use of single-cell exome
sequencing, AHNAK, LRRK2, SRGAP3, and USP6 have
been found to be the key mutated genes in the ccRCC
patient without VHL mutations [16]. In this study, al-
though we found some differences in their expression
patterns (Figure 6), it is hard to interpret the role of the
4 genes in ccRCC in terms of the expression patterns.
We found that gains of chromosomes and some abnor-
mal structures were the major chromosomal abnormal-
ities in the two cell strains. Thus, our findings add novel
information to the cytogenetic abnormality of ccRCC
with different metastatic potentials and make the cell
lines good tools to study RCC without VHL mutations.
Our cytometry assay revealed that the two cell lines
were positive for CD44 but negative for CD133, CD105,
Figure 6 Relative mRNA levels of genes of interest in MRCC and NRCC.
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mRNA levels in tumors can distinguish between RCC sub-
types and RCC subtypes from oncocytoma and predict
RCC metastasis [17]. Unexpectedly, the two cell lines were
negative for CD105, a possible marker of ccRCC-initiation
cells [10]. Recent studies have confirmed that CD133 isFigure 7 Western blotting for the detection of IkBα
degradation following TNFα treatment.not detectable in RCC cells and tissues [10,18]. Here we
found CD24 positivity was more frequent in MRCC than
in NRCC and the same was true for CD56 (Figure 4).
CD24 is a cancer stem-like cell biomarker whose expres-
sion in tumors is associated with malignant phenotype
and poor prognosis of ccRCC and other cancers [19,20].
CD56 has been found to be expressed in 15%-18% of
ccRCC and associated with poor outcome [21]. Although
no markers, single or combined, could be defined un-
equivocally to specifically identify cancer stem cells in a
given solid tumor so far [22], our data indicate that CD24-
positive subpopulation might be the most likely stem-like
cells that are related to ccRCC metastasis. NRCC and
MRCC are epithelial-origin, but MRCC tends to be more
mesenchymal-like (Figure 4). Acquisition of mesenchymal
properties by epithelial cells, a process called epithelial-
mesenchymal transition (EMT), can partially explain the
metastatic potential of MRCC.













1 Primary 5/5 No 0/5 0/5 0/5
2 Primary 5/5 Yes 4/5 4/5 2/5
3 Metastasis 5/5 Yes 4/5 4/5 3/5
4 Metastasis 5/5 Yes 4/5 2/5 3/5
5 Metastasis 5/5 Yes 5/5 3/5 5/5
6 Metastasis 5/5 Yes 5/5 3/5 5/5
NRCC
1 Primary 4/5 No 0/5 0/5 0/5
2 Primary 5/5 No 0/5 0/5 0/5
3 Primary 5/5 No 0/5 0/5 0/5
† a, the number of mice with the event of interest (tumorigenicity, metastasis, hemorrhagic ascites or cachexy);
b, total number of mice orthotopically transplanted with the minced tumor masses.
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mokine from lymphocytes, endothelial cells and mesen-
chymal cells within the microenvironment are necessary
to maintain cancer “stemness” [23], the expression of
these factors in cancer cells is important in maintaining
their invasive and metastatic potential. In this study, we
found that the transcriptional levels of IL-6, VEGF,
HIF2α, TNFα, MMP2, and RhoC were higher in MRCC
than in NRCC. Expression of VEGF, MMP2, and RhoC
in ccRCC is associated with metastasis and poor progno-
sis or used to evaluate the effectiveness of therapies on
metastatic RCC [24-26]. The expression of IL-6 and
TNFα is significantly elevated in high malignant RCC
cells compared to low malignant RCC cells [27]. Fur-
thermore, plasma levels of TNFα and IL-6 are associated
with poor survival of RCC patients [28]. Interestingly,
the expression of HIF2α, rather than HIF1α, was signifi-
cantly elevated in MRCC than in NRCC (Figure 6). The
HIFα subunits increase target gene transcription in hyp-
oxic cells. However, HIF1α uniquely activates glycolytic
enzyme genes, while HIF2α preferentially activates VEGF
and cyclin D1. HIF2α promotes while HIF1α inhibits c-
Myc transcriptional activity and cell cycle progression in
RCC [29]. HIF1α negatively regulates Wnt/β-catenin sig-
naling, while HIF2α is required for β-catenin activation
in RCC cells and for RCC proliferation [30]. HIF1α/
HIF2α imbalance in cancer cells might be important for
RCC growth and metastasis.
The expression patterns of IL-6 and TNFα indicate that
NF-κB signaling pathway is more active in MRCC than in
NRCC. This result was later confirmed by the western blot
findings that IκBα was more degraded in MRCC than in
NRCC following the treatment with TNFα (Figure 7).
Thus, NF-κB is not only critical in regulating RCC biology
that pose challenge to conventional therapy [31], but also
important in promoting ccRCC metastasis.Conclusions
We established two ccRCC cell lines named MRCC and
NRCC from clinical specimens of two Chinese patients.
ccRCC cells from metastatic tumor have more malignant
and metastatic potential than those from primary tumor
following long-term in vitro cultures. CD24 positivity
and the transcription levels of pro-angiogenic, pro-
inflammatory and growth signaling factors in cancer
cells are associated with ccRCC invasiveness and metas-
tasis. These comparable cell lines will be powerful tools
to improve our knowledge about ccRCC biology and
metastasis.
Methods
Clinical specimens and primary culture
A 62-year-old male patient (No.375771) underwent sur-
gical resection for a growing lesion in the spine at the
2nd affiliated hospital on February 6, 2006. This patient
had received nephrectomy to excise ccRCC 10 years ago.
He was pathologically diagnosed as ccRCC metastasized
to bone and tumor nuclear grade was Fuhrman III. A
49-year-old male patient (No.378570) underwent neph-
rectomy at the same hospital on April 3, 2006. This pa-
tient was histopathologically diagnosed as ccRCC. The
tumor nuclear grade was Fuhrman II. The fresh surgical
specimens were immediately transported to our labora-
tory in ice-cold PBS, and processed for cell culture
within 60 min after surgery. Primary cell culture was
performed as previously described [32]. The experimen-
tal protocol was approved by the Institutional Ethical
Review Board of Second Minitary Medical University
conformed to the ethical guidlines of the 1975 Declar-
ation of Helsinki. An informed consent was obtained
from each patient. The two patients were followed since
receiving the surgery in our hospital. The patient with
metastatic ccRCC died of ccRCC six months after the
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graphically diagnosed as having a tumor in pancreas in
2008 and died in 2009. However, we were not sure if the
tumor was pancreas-originated cancer or metastasis
from original ccRCC because this patient didn’t receive
further surgery or biopsy.
Morphology and electron microscopy (EM)
Morphology of the cells and their parental tissues
was observed using inverted phase-contrast microscope
(Leica DMI 3000B, Germany) following routine H&E
staining as previously described [32]. Cells (5 × 106) were
processed as previously described [9] and examined
using an electron microscope (Hitachi H-7650, Tokyo,
Japan).
Cell growth and invasion assay
A total number of 3 × 104 cells for each cell line
suspended in 12 ml DMEM (GIBCO, Grand Island, NY)
with 10% FCS (GIBCO) were plated in 24-well plates.
Cells in every three wells were counted once a day. The
average numbers were used to generate the growth
curve. Anchorage independent growth potential was
evaluated by double-layered soft agarose culture system.
After cultured for 15d, the cells were stained with crystal
violet and colony formation was counted under a light
microscope (Leica). Cell invasion assay was performed
using 24-well tissue culture plates (8-μm pore size,
Transwell, Corning, NY). The bottom of the culture in-
serts was coated with 20 μg of Matrigel (BD Biosciences,
Bedford, MA). The cells (5 × 104) in 0.1 ml medium with
1% FCS were placed in the upper chamber and the lowerTable 3 Primers and PCR amplification condition
Genes
Primers














AHNAK GTGCCACCATCTACTTTGACA GCTGGCTTCCTTCTGTTchamber was loaded with 0.2 ml medium containing
10% FCS. After cultured for 24 h in 37°C, 5% CO2, the
cells that migrated to the lower surface of filters was
quantified by counting 10 independent symmetrical vis-
ual fields under the microscope to determine the inva-
sion rate. Each assay was performed in triplicate.
Karyotype analysis
Chromosomal preparation and R-banding were performed
as previously described [33]. A total of 100 metaphase
spreads were observed under a microscope (Leica,
DM6000B) and 30 complete karyotypes were prepared to
determine the chromosome number of each cell line using
CW4000 software (Leica).
Flow cytometry
Cell markers were determined using the following
monoclonal antibodies: anti-CD44-Phycoerythrin (PE),
anti-CD74-PE, anti-CD105-FITC, anti-CD56-FITC, anti-
CD24-FITC, and anti-CD99-FITC (Biolegend, UK); anti-
CD133-PE (Miltenyi, Germany); anti-vimentin (Santa
Cruz, CA); anti-N-Cadherin (BD Biosciences); anti-E
-cadherin, anti-EpCAM (Cell Signaling, MA). Briefly,
both cell lines were cultured at the same condition.
Then 5 × 105 cells were washed twice and resuspended
in PBS with 1% FCS, and incubated either in the primary
antibody (anti-CD133, CD44, CD74, CD105, CD56,
CD24, and CD99) conjugated with FITC or PE for
30 min on ice, or incubated in primary antibodies to
vimentin, E-cadherin, N-cadherin, or EpCAM and then
washed and incubated with secondary antibody conju-
gated with FITC. Cells were then washed twice with PBSPCR condition0)
CCA
95°C for 10 min. 45 cycles of 95°C for 10 s, 60°C for 10s,






95°C for 15 min, 40 cycles of 95°C for 10s, 60°C for 45 s
GG
AAGAG 94°C for 3 min, 40 cycles of 94°C for 15 s, 60°C for 30s, 72°C
for 30s
TCCG
30 cycles of 94°C for 30s, 58°C for 1 min,72°C for 1 min
GATG
GGTT
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within 1 h using a flow cytometer (FACSCalibur, BD
Biosciences). Cell debris and fixation artifacts were ex-
cluded by appropriate gating. The acquisition process
was stopped when 10,000 events were collected in the
population gate. CellQuest software (BD Biosciences)
was used for data acquisition and analysis.
The cells for cell cycle analysis were grown at the same
pace and fixed with 70% ethanol at 4°C for more than
2 h and then washed twice. Fixed cells were stained with
100 mg/ml propidium iodide containing 100 mg/ml
RNase. Samples on ice were immediately analyzed on
the flow cytometer with CellQuest software to separate
G0/G1, S, and G2/M phases.
Quantitative RT-PCR
The cells were cultured under the same condition in 6-
well plates. Total RNA was isolated and reverse tran-
scribed to cDNA, and subjected for quantitative PCR as
previously described [34]. The assay for each gene was
repeated for 4–5 times. The primers for the amplifica-
tion of IL-6, TNFα,VEGF, MMP2, HIF1α, HIF2α, GSK3β,
RhoC, USP6, AHNAK, LRRK2, and SRGAP3 as well as
their corresponding amplified conditions are summa-
rized in Table 3, GAPDH, and β2-microglobulin were
used as internal control.
Western blot
The cells were in vitro treated with 10 ng/mL TNFα
(R & D Systems, MN) at different time points and
then harvested. Cytosolic protein extracts were pre-
pared as previously described [35]. Cytosolic IκBα
was determined by immunoblotting with an anti-IκBα
antibody (Cell Signaling). β-actin was detected by im-
munoblotting with antibody against β-actin (Cell Signal-
ing). Genetools software (version 4.02, Synoptics,
Cambridge, England) was used to quantify the signal
strength of the bands.
Subcutaneous and orthotopic transplantation
Six-week-old male BALB/c nude mice were purchased from
Shanghai Experimental Animal Centre, Chinese Academy of
Science (Shanghai, China) and treated in accordance with the
American Association for the Accreditation of Laboratory
Animal Care guidelines. The cells were washed and re-
suspended in 200 μl PBS, and subcutaneously injected into
the flanks of the mice (2 × 106/mouse). The mice were
sacrificed when tumors grown up to 10 mm in diameter. The
tumors were excised and mechanically minced with scissors
in a sterile manner. Half of the minced tissues were subjected
for primary culture, another half of the minced tumors
of 1-2 mm in diameter were transplanted into renal
subcapsules of anaesthetized mice to establish SOI
model as previously described [36]. The mice weresacrificed before dying. The tumor tissues were
transplanted for the next round of SOI. All visceral or-
gans were fixed in 10% formalin. Metastasis was con-
firmed using gross and histological examination.
Statistical analysis
Student’s t test was used to determine the differences in
the colony-formation rates, invasion rates, and gene ex-
pression levels of the two cell lines. All statistical tests
were two-sided and performed using the Statistical Program
for Social Sciences (SPSS16.0 for Windows, Chicago, IL). A
p value of <0.05 was considered as statistically significant.
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